Pfizer and Valenva are seeking regulatory approval from the Food and Drug Administration for a Lyme disease vaccine in development that's more than 70% effective against the tick-borne illness.

The new COVID-19 vaccine rolled out across the country last month, giving people access to the most recent versions of the Moderna, Pfizer, and Novavax shots. But, given that you have options, which ...

A Lyme disease vaccine produced by Pfizer and Valneva was deemed 70 percent effective by the companies after they reviewed the results from a phase 3 trial. If approved by regulators, it would be the ...

COVID-19 vaccine recommendations could be changing, according to the U.S. Food and Drug Administration. FDA leaders said on May 20 that clinical trials will be required to approve annual COVID-19 ...

Four doses of an experimental vaccine to protect against Lyme disease reduced the number of tick-borne infections by more than 70 percent, according to Pfizer and Valneva, the pharmaceutical companies ...

Amid uncertainty over how the Trump administration would approach mRNA COVID-19 vaccines for the upcoming respiratory virus season, the FDA has approved updated shots from Pfizer and Moderna. But ...

With an expanded usage recommendation from the CDC's Advisory Committee on Immunization Practices (ACIP), pneumococcal conjugate vaccines from Pfizer and Merck are poised to add millions more eligible ...

Pfizer and Valneva said Monday their Lyme disease vaccine showed more than 70% efficacy in a late-stage study, even as it missed its main goal. Subscribe to read this story ad-free Get unlimited ...

LONDON, April 1 (Reuters) - Vaccine makers Pfizer (PFE.N), opens new tab and BioNTech (22UAy.DE), opens new tab halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to ...

Vaccine makers Pfizer PFE.N and BioNTech 22UAy.DE halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too low to ...